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T cell–mediated immunity requires that T 
lymphocytes undergo both clonal expansion 
and diff  erentiation to produce bioactive cyto-
kines and cytolysins. The cytokine IFN-γ plays 
a major role in protection against intracellular 
pathogens (1–3) and tumors (4) and is pro-
duced in large amounts by helper CD4+ T 
lymphocytes. When T cells diff  erentiate to 
produce IFN-γ exclusively, they are termed 
Th1 cells, whereas those that produce IL-4, 
IL-5, and IL-13, which resist helminth infec-
tion and   mediate allergy, are termed Th2 
(for review see references 5 and 6). Thus, the 
nature of the   cytokines produced by T cells 
signifi  cantly   impacts upon host resistance and 
immunopathology (2, 7).
DCs are specialized antigen-presenting cells 
that initiate immunity (8, 9). This is illustrated 
by the fact that the selective targeting of anti-
gens to DCs in immune or lymphoid organs 
  of mice markedly improves the effi   ciency of 
clonal expansion (10, 11) and protective im-
munity (12, 13). DCs support several distinct 
pathways of T cell diff  erentiation in tissue cul-
ture, such as Th1 and Th2 (14). Their capacity 
to induce IFN-γ in CD4+ T cells is ascribed to 
secretion of an important cofactor, IL-12 (15–17; 
for review see references 2, 8, and 18).
The biology of the DC–T cell interaction is 
also infl   uenced by the existence of diff  erent 
types of DCs, or DC subsets. One expresses the 
endocytic receptor DEC-205 (here “DEC”; 
reference 19) as well as a marker of unknown 
function, CD8αα (20). CD8+ or DEC+ DCs 
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by targeting the LACK antigen from Leishmania major within an antibody to CD205 (DEC-
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pathway was obscured with nontargeted LACK, which was presented by both DC subsets. 
This in situ analysis points to CD70 as a decision maker for Th1 differentiation by CD205+ 
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indicate that two DC subsets have innate propensities to differentially affect the Th1/Th2 
balance in vivo and by distinct mechanisms.
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mediate the presentation of antigens on both MHC class I 
and II products, leading to clonal expansion of killer and Th 
cells, respectively (21–23). Another DC subset expresses a 
distinct uptake receptor, DCIR2, recognized by the 33D1 
mAb (24, 25) and lacks CD8αα. It primarily expands CD4+ 
helper lymphocytes (26). When antigen is taken up by iso-
lated DEC+ DCs, they trigger T cells to produce primarily 
IFN-γ, whereas DEC− DCs induce either IL-4 exclusively 
or both IFN-γ and IL-4 (27, 28). Consistent with these ob-
servations, the IL-12 cofactor for IFN-γ production is pro-
duced at higher levels by DEC+ DCs (15, 18, 29, 30).
The function of DC subsets in the induction of cytokine-
producing T cells has yet to be analyzed directly in intact 
lymphoid tissues. A signifi  cant enigma is that patients and 
mice that are genetically defi  cient in IL-12 or IL-12Rβ1 re-
tain the capacity to produce low levels of IFN-γ and to resist 
intracellular infections (31–37). These observations indicate 
the existence of an alternative pathway for IFN-γ induction 
(for review see reference 38). Here we separately target anti-
gen in vivo to two major subsets of DCs, using the antigen 
LACK (39) from the parasite Leishmania major. L. major infec-
tion of mice is an experimental model that has helped unravel 
Th1/Th2 CD4+ diff  erentiation and the role of IL-12 in vivo 
(40–42; for review see reference 43). Surprisingly, we fi  nd 
that the DEC+ subset, which proves to be the more powerful 
inducer of IFN-γ in vivo, does so in the absence of IL-12. 
Instead, the membrane-bound cofactor CD70 is vital. These 
fi  ndings outline a new route to the production of a pivotal 
protective cytokine, IFN-γ, and contrast the mechanisms used 
by DC subsets to initiate immunity.
RESULTS
Effi  cient antigen presentation after the targeting of LACK 
to DC subsets
To examine the role of two major DC subsets in vivo, we 
selectively delivered the L. major LACK antigen (39) to DEC+ 
33D1− and DEC− 33D1+ DCs by producing chimeric anti-
DEC and 33D1 LACK chimeric mAbs (Fig. S1, available 
at http://www.jem.org/cgi/content/full/jem.20070176/DC1). 
We injected the chimeric LACK mAbs s.c. or i.p., together 
with the maturation stimuli αCD40 and poly IC, and used 
LACK-specifi  c TCR transgenic CD4+ T cells as reporters 
for the successful capture and processing of antigen by DCs 
in vivo. We found that CD11c+ cells from either lymph nodes 
Figure 1.  𝗂DEC and 33D1 mAbs target LACK in vivo to distinct DC 
subsets. (A) BALB/c mice (fi  ve per condition) were immunized i.p. with 
αDEC-LACK, 33D1-LACK, LACK, and Ig-LACK in the presence of αCD40 
and poly IC, or with PBS. 12 h later, splenocytes were enriched for CD11c+ 
cells by MACS+ selection and separated into DEC+ and DEC− subsets (see 
Materials and methods). The DCs were added to thy-1.1+ CFSE-labeled, 
LACK-specifi  c TCR transgenic T cells, and proliferation was assessed by 
CFSE dilution 3.5 d later. Representative of three experiments. (B) 3 × 10
6 
CFSE-labeled TCR transgenic cells as in A were administered i.v. to thy-
1.2+ mice 1 d before immunization i.p. with graded doses of αDEC-LACK, 
33D1-LACK, Ig-LACK, or LACK protein. Spleens were harvested at 3 d to 
enumerate thy-1.1
+ T cells that had diluted CFSE. The expansion of trans-
genic T cells is displayed as total cell numbers on the left, and representa-
tive CFSE dilution plots, gated on thy-1.1+ LACK transgenic CD4+ T cells 
in response to the indicated doses of fusion mAb or LACK protein, are on 
the right.JEM VOL. 204, May 14, 2007  1097
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(Fig. S2) or spleen (not depicted) were selectively responsible 
for LACK presentation. When the two subsets of splenic 
CD11c+ DCs were separated on the basis of DEC expres-
sion, the DEC+ DCs exclusively stimulated clonal expansion 
after injecting DEC-LACK, but not 33D1-LACK, whereas 
the DEC− DCs were exclusively active after injection of 
33D1-LACK (Fig. 1 a), each over a wide range of DC to T 
cell doses (1:3–1:27; not depicted). In contrast, soluble LACK 
was presented by both DC subsets, and there was no presen-
tation of control Ig-LACK (Fig. 1 a). To assess antigen pre-
sentation in vivo, we adoptively transferred CFSE-labeled, 
allotype (thy-1.1) -marked T cells into the LACK-targeted 
mice. Both chimeric mAbs were at least 100-fold more effi   -
cient than soluble LACK at initiating clonal expansion in 
vivo (Fig. 1 b, left); e.g., 0.03 μg of each fusion mAb was 
more eff  ective in triggering CFSE dilution than 3 μg of non-
targeted LACK (Fig. 1 b, right). Thus, the DEC and 33D1 
mAbs faithfully and effi   ciently deliver LACK for presentation 
by the appropriate DCs, whereas the more standard use of 
nontargeted antigen leads to presentation by both subsets.
Contrasting pathways of T cell differentiation via DC subsets
To examine T cell diff  erentiation in a primary immune response 
to targeted antigen, we measured IFN-γ production by intra-
cellular cytokine staining. All forms of LACK induced IFN-γ 
as long as a DC maturation stimulus was also administered 
(Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20070176/DC1; references 13 and 44). Consistent with 
Figure 2.  Contrasting cytokine production by T cells immunized 
with different forms of LACK. (A) BALB/c mice were injected i.p. with 
PBS, 10 μg αDEC-LACK, 10 μg 33D1-LACK, 10 μg control Ig-LACK, or 
30 μg LACK in the presence of αCD40 and poly IC. 3 wk later, splenocytes 
were enriched for CD4+ cells (MACS selection) and restimulated with 
CD11c+ cells plus LACK-dominant peptide. 2 d later, the numbers of IFN-γ– 
(left) and IL-4– (right) producing cells were revealed by ELISPOT. Three 
experiments with two mice per group. (B) As in A, but mice were both 
primed and boosted at 3 wk with different forms of LACK. 6 d later, anti-
LACK–specifi  c antibody titers and isotypes were quantifi  ed by ELISA. Each 
symbol is an individual experiment. (C) 3 × 106 CFSE-labeled, thy-1.1+ 
LACK-specifi  c TCR transgenic cells were transferred i.v. into thy-1.2+ 
BALB/c mice. 1 d later, the mice were immunized i.p. with the different 
LACK antigen forms in the presence of αCD40 and poly IC, 106 L. major 
metacyclic promastigotes, or PBS. 6 d later, the priming of LACK-specifi  c 
transgenic T cells was assessed for intracellular IFN-γ production by gat-
ing on thy-1.1+ splenocytes (left), or for IL-4 production by ELISPOT of 
positively selected thy-1.1+ splenocytes restimulated for 4 h in the pres-
ence of PMA and ionomycin (right). Representative of three experiments.1098  IL-12-INDEPENDENT, CD70-DEPENDENT IFN-γ SECRETION VIA DEC+ DCS | Soares et al.
prior research (45), we found that the combination of agonistic 
anti-CD40 and TLR3 ligand, poly IC, was the most eff  ective 
stimulus for a primary response to all LACK antigen immu-
nization forms (Fig. S3). Poly IC by itself induced IFN-γ 
production only when LACK antigen was targeted to DEC+ 
DCs (Fig. S3). However, poly IC did act synergistically with 
αCD40 to increase IFN-γ secretion when DEC− DCs were 
targeted with 33D1-LACK (Fig. S3). The targeting of LACK 
to maturing DCs enhanced immunization relative to soluble 
LACK or Ig-LACK control, with DEC-LACK being more 
eff  ective than 33D1-LACK (Fig. S4). The peptides recog-
nized in the immunized mice (Fig. S5) contained the LACK 
158–173 sequence I  C  F  S  P  S  L  E  H  V  S  G  S  W  D  , previously de-
fi  ned to be presented on the I-Ad MHC class II molecule of 
BALB/c mice (39). These initial data showed that targeting 
to either DC subset resulted in IFN-γ production in vivo.
We next compared the production of IFN-γ to IL-4 after 
the targeting of antigens to maturing DC subsets. DEC-LACK 
immunization exclusively primed for IFN-γ and not IL-4, 
even though the BALB/c mice we used were prone to pro-
duce Th2 responses (Fig. 2 a). In contrast, soluble LACK and 
33D1-LACK induced IL-4 and less IFN-γ (Fig. 2 a). Similar 
results were obtained when we replaced poly IC with LPS 
(not depicted). These distinct outcomes were corroborated by 
the isotype of the anti-LACK antibody response. After DEC-
LACK immunization, mice primarily produced antibodies of 
the IgG2a isotype, which is favored by IFN-γ–producing 
helper CD4+ T cells, whereas 33D1 and soluble LACK induced 
Figure 3.  𝗂DEC-LACK induces IFN-𝗄 secretion by an IL-12–
independent pathway. (A) IL-12p40−/− mice and control littermates 
were immunized i.p. as indicated in Fig. 2 and on the x axis. 3 wk later, the 
frequency of IFN-γ+ CD4+ CD3+ splenic T cells was determined by intra-
cellular staining (left), or CD4+ splenocytes were restimulated in vitro with 
CD11c+ cells, medium, or LACK peptide for 36–48 h to measure IL-4–
secreting cells by ELISPOT (right). (B) As in A, but each row shows a different 
dose of the different forms of LACK antigen. (C) As in A, but WT and IL-12 
KO mice were immunized with P. yoelli circumsporozoite protein (CSP), 
either 10 μg DEC-CSP, 10 μg 33D1-CSP, and 10 μg Ig-CSP in the presence 
of αCD40 and poly IC, or PBS. Representative of three, three, and two 
individual experiments with two pooled mice per condition, respectively.JEM VOL. 204, May 14, 2007  1099
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several isotypes, including particularly high titers of IL-4–
  dependent IgG1 antibodies (Fig. 2 b). To verify our results with 
monoclonal T cells, we adoptively transferred specifi  c thy-1.1-
marked TCR transgenic T cells into mice that were primed 
with diff  erent forms of LACK. Again, DEC-LACK induced 
IFN-γ, but not IL-4, whereas 33D1-LACK and soluble LACK 
induced both IFN-γ and IL-4 (Fig. 2 c). Leishmania organisms 
produced a strong but exclusive IL-4 response, typical of BALB/c 
mice (Fig. 2 c). Therefore, in vivo targeting of antigen to diff  er-
ent DC subsets leads to diff  erent T cell outcomes.
IL-12–independent IFN-𝗄 production via DEC+ DCs
IL-12 p40/p35 heterodimer is a cofactor for the diff  erentia-
tion of IFN-γ–producing cells (16, 46, 47). To determine the 
role of IL-12 in T cell diff  erentiation after antigen targeting to 
DCs, we immunized IL-12 p40 mutant mice (IL-12 p40−/−). 
Surprisingly, DEC-LACK immunization of IL-12 p40−/− 
mice induced IFN-γ secretion and no IL-4, and the frequency 
of IFN-γ–producing cells was comparable to heterozygous 
littermates (Fig. 3 a) and WT BALB/c mice (not depicted). 
This was the case over a wide range of doses of DEC-LACK 
(Fig. 3 b). However, IFN-γ production was ablated in IL-12 
p40−/− mice that were immunized with 33D1-LACK, 
whereas IL-4 was made in increased amounts. Soluble LACK 
induced less IFN-γ but more IL-4 in IL-12 p40−/− mice (Fig. 
3 a), as expected from its targeting to both DC subsets. To 
determine if these results were restricted to the LACK antigen, 
we repeated the same experiment using circumsporozoite 
protein from Plasmodia as described previously (44). DEC-
CS, but not 33D1-CS, again induced IFN-γ in an IL-12–
  independent manner (Fig. 3 c). Thus, in contrast to expectations 
from prior research with isolated DCs, DEC+ DCs induced 
IFN-γ in the absence of IL-12 in vivo.
DEC− DCs obtain IL-12 from DEC+ DCs to induce IFN-𝗄
To further analyze the function of isolated DC subsets, we in-
jected mice with diff  erent forms of LACK, separated the DEC+ 
and DEC− DCs, and tested their capacity to diff  erentiate 
Figure 4.  DEC− DCs differentiate Th2 type CD4+ T cells but prime 
IFN-𝗄 secretion with IL-12–bearing DEC+ DCs. (A) BALB/c mice were 
immunized i.p. as indicated in Fig. 2 and the right inset for 10–12 h. DEC+ 
and DEC− subsets were sorted from spleens and added for 3.5 d to thy-
1.1+ CFSE-labeled, LACK-specifi  c TCR transgenic cells. IL-2, IFN-γ, IL-4, 
and IL-5 production were measured in the supernatants by ELISA. The 
symbols represent individual experiments with fi  ve mice per condition, and 
the horizontal bars represent the mean between the different experiments. 
(B) As in A, but the DC subsets from either WT (shown) or IL-12−/− 
mice (see Fig. S6) were used to stimulate T cell proliferation (CFSE dilution, 
x axis) as well as IFN-γ production (y axis; monensin was added overnight 
in the absence of any restimulation at day 3). (C) DEC− DCs were isolated 
from mice given 33D1-LACK, LACK in the presence of αCD40 and poly IC, 
or PBS 12 h earlier (same cells as B), but we then added an equal number 
of DCs from WT (WT) and IL-12p40−/− mice as indicated on the x axis. The 
donor mice had been given anti-CD40 and poly IC, but no LACK antigen, 
12 h beforehand (mature), or just PBS. As in B, T cell proliferation and 
IFN-γ production were monitored. One of two similar experiments.1100  IL-12-INDEPENDENT, CD70-DEPENDENT IFN-γ SECRETION VIA DEC+ DCS | Soares et al.
TCR transgenic T cells in vitro. After selective targeting, 
both DC subsets induced comparable levels of IL-2 (Fig. 4 a, 
top left), indicating that both types of DCs were presenting 
antigen eff  ectively. The DEC+ DCs induced the production 
of IFN-γ (Fig. 4 a, top right), but the isolated DEC− DCs 
no longer stimulated IFN-γ production and only induced 
IL-4 and IL-5 (Fig. 4 a, bottom). These data confi  rm prior 
work with CD8+ and CD8− DC subsets targeted with anti-
gen in vitro (27, 28).
When we compared DCs from WT and IL-12 p40−/− 
mice, both subsets induced vigorous transgenic T cell prolif-
eration, as shown by CFSE dilution (Fig. 4 b and Fig. S6, 
x axis, which is available at http://www.jem.org/cgi/content/
full/jem.20070176/DC1). However, IFN-γ was only pro-
duced when the T cells were cultured with DEC+ DCs, and 
this was the case with DCs from either WT (Fig. 4 b) or IL-12 
p40−/− mice (Fig. S6, y axis). When we injected soluble 
LACK, both DC subsets induced strong T cell proliferation, 
but again only DEC+ DCs induced IFN-γ (Fig. 4 b and 
Fig. S6). Similar results were obtained whether we harvested the 
DCs from mice that did not receive a maturation stimulus, or 
when the maturation stimulus was anti-CD40, poly IC, LPS, 
or both poly IC or LPS and anti-CD40 (not depicted). The 
fact that only the DEC+ DCs induced IFN-γ secretion after 
soluble LACK protein presentation strongly suggests that the 
capacity to induce IFN-γ is a property of the DC subset and 
not the receptor (DEC205 or DCIR2) that was targeted.
Because isolated DEC− DCs did not induce IFN-γ in 
vitro (Fig. 4, a and b) but did so in vivo (Fig. 3, a–c), we hy-
pothesized that these DCs obtained the required IL-12 from 
DEC+ DCs. DEC+ DCs are the major producer of IL-12 
(15, 18, 29, 30). We found that 105 DEC+ DCs from mice 
injected with αCD40 and poly IC secreted 805 pg/ml IL-12 
(against a background of 64 pg/ml) when cultured for 2 d, 
whereas DEC− DCs produced 237 pg/ml (not depicted). 
We therefore repeated the in vitro experiments with the 
antigen targeted to WT DEC− DCs, but we added WT or 
IL-12−/− DEC+ DCs from mice given only anti-CD40 and 
poly IC (without any LACK antigen). Supplementation of 
the antigen-targeted DEC− DCs with antigen-free DEC+ 
DCs restored IFN-γ production, but only if the DCs were 
mature and from WT mice (Fig. 4 c, left). These data indicate 
that maturing DEC+ DCs produce suffi   cient IL-12 to allow 
DEC− DCs to induce IFN-γ.
Figure 5.  CD70 mediates the stimulatory function of DEC+ DCs, 
but not DEC− DCs. (A) Mice were immunized i.p. as in Fig. 2 and as 
shown at the top for 10–12 h. Sorted DEC+ and DEC− subsets were 
added for 1 d to thy-1.1+ CFSE-labeled, LACK-specifi  c TCR transgenic 
cells, and the CD11c+ DCs (the only CD70+ cells in the cultures) were 
monitored by FACS for reactivity to αCD70 (dotted line) or isotype con-
trol mAb (gray). (B) As in A, but the cells were cultured for 3.5 d in the 
presence of αCD70 or control IgG2b (1 μg/ml). Inhibition of T cell 
growth, assessed by CFSE dilution, is noted with arrowhead and arrows. 
(C) As in B, but BALB/c mice were injected with αDEC-LACK alone and in 
the presence of αCD40, poly IC, or both. IFN-γ production by proliferating 
LACK transgenic cells was determined by intracellular cytokine staining. 
(D) As in B, but T cell activation was monitored by CD69 staining at days 
1.5 and 3.5. (E) As in B, but αCD70 was added 1 d after co-culture. B–E 
are representative of four, two, fi  ve, and two experiments, respectively, 
with fi  ve mice per condition.JEM VOL. 204, May 14, 2007  1101
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CD70 is essential for the function of DEC+ DCs in vitro
To determine how IL-12 p40−/− DEC+ DCs induced IFN-γ, 
we considered CD70, a member of the TNF family of co-
stimulatory molecules (for review see reference 48). We had 
found CD70 to be expressed in ongoing studies of DCs ma-
turing in vivo in response to NKT cells (49). In mice injected 
for 12 h with poly IC and anti-CD40, low levels of CD70 
were expressed intracellularly, but not at the cell surface (not 
depicted), by both DEC+ and DEC− DCs (Fig. S7, available 
at http://www.jem.org/cgi/content/full/jem.20070176/DC1). 
Surprisingly, 1 d after DC subsets were added to LACK-
specifi  c TCR transgenic T cells in culture, CD70 was up-
regulated and expressed at the cell surface, but exclusively by 
antigen-targeted DEC+ DCs (Fig. 5 a). Another TNF family 
member, 4-1BBL, was not detected on the same DCs (not 
depicted). We then found that it was not necessary to admin-
ister maturation stimuli to mice for antigen-targeted DEC+ 
DCs to up-regulate CD70 upon co-culture with T cells. These 
data indicate that surface expression of CD70 is a property of 
DEC+ DCs presenting antigen to T cells.
We next tested the eff  ect of a blocking mAb to CD70 
(50) on co-cultures of DCs and LACK-specifi  c TCR trans-
genic T cells. The anti-CD70 mAb, but not an isotype con-
trol (or two other isotype-matched mAbs that reacted with 
DCs, anti-CD8 and anti-FcγR; not depicted), completely 
blocked T cell proliferation induced by DEC+ DCs (Fig. 5 b, 
left, arrow) as well as the production of IFN-γ (not depicted). 
This was the case when DEC+ DCs had captured DEC-
LACK or soluble LACK in vivo (Fig. 5 b, arrows), or when 
DEC+ DCs were presenting LACK peptide in vitro (Fig. 5 b, 
arrowhead). In contrast, anti-CD70 did not block presenta-
tion by DEC− DCs targeted with 33D1-LACK, soluble 
LACK, or LACK peptide (Fig. 5 b). Identical results were 
obtained with DCs from IL-12 p40−/− mice; i.e., DEC+ DCs 
required CD70 to stimulate T cell proliferation and IFN-γ 
production (Fig. S6). We also found that in vivo–targeted 
DEC+ DCs did not require TLR or CD40 engagement to 
effi   ciently induce IFN-γ production from LACK transgenic 
T cells in a CD70-dependent manner (Fig. 5 c). Therefore, 
CD70 is required by DEC+ DCs to stimulate T cell responses, 
but not by DEC− DCs, even when the two DC subsets are 
targeted with the same form of antigen, LACK protein, or 
LACK peptide.
To further address the consequences of CD70 blockade, 
we fi  rst verifi  ed that αCD70 did not alter the number of 
DCs in the culture (not depicted) or inhibit the early steps in 
antigen presentation because the CD69 activation antigen 
was up-regulated normally when αCD70 was present for 1.5 
or 3.5 d (Fig. 5 d). To test if αCD70 could block IFN-γ 
production after T cell proliferation had taken place, we 
added the blocking mAb to co-cultures of DC subsets and 
LACK transgenic T cells at 1 (Fig. 5 e) or 2 d after the ini-
tiation of the DC–T cell co-culture (not depicted). αCD70 
at these later time points did not block T cell proliferation 
(Fig. 5 e). However, it completely inhibited IFN- γ induc-
tion by antigen-bearing DEC+ DCs, but not IL-4 produc-
tion induced by DEC− DCs (Table I), showing that CD70 
contributes to both T cell proliferation and IFN-γ produc-
tion by DEC+ DCs.
To exclude the possibility that αCD70 could be acting on 
CD4+ T cells, we determined CD70 expression levels on 
LACK TCR transgenic cells 3 d after stimulation by DCs. 
Presentation by DC subsets loaded with either DEC-LACK 
or 33D1-LACK induced comparable expression of cell sur-
face (not depicted) and intracellular CD70 by LACK trans-
genic cells in vivo (Fig. S8, available at http://www.jem
.org/cgi/content/full/jem.20070176/DC1). However, αCD70 
only blocked stimulation by DEC+ DCs (Fig. 5, c and e), 
which selectively expressed cell surface CD70 (Fig. S7). Col-
lectively, the data in Figs. 4 and 5 reveal that DEC+ DCs 
have two mechanisms to induce IFN-γ from CD4+ T cells: 
a direct pathway that requires CD70 but not IL-12, and an 
Table I.  αCD70 blocks IFN-γ secretion by LACK transgenic cells primed by DEC+ DCs, but not by DEC− DCs
 
Form of LACK antigen to load DCs
DC Subset Cytokine pg/ml Blocking mAb αDEC-LACK 33D1-LACK Ig-LACK LACK None LACKpep
0.02 μM
DEC+ DCs
IFN-γ
IgG2b 2,048 20 −66 463 4 2,189
αCD70 51 34 16 −76 −61 23
IL-4 IgG2b −41 −89 −92 −77 −90 −30
αCD70 −29 −71 −89 −70 −93 −79
DEC− DCs
IFN-γ IgG2b 13 −71 25 −76 −44 80
αCD70 15 19 23 11 −60 25
IL-4
IgG2b −54 471 −64 406 −96 485
αCD70 −43 498 −70 646 −79 602
BALB/c mice (fi  ve mice per condition) were immunized for 10–12 h with 10 μg αDEC-LACK, 10 μg 33D1-LACK, 10 μg Ig-LACK, and 30 μg LACK protein in the presence of 
αCD40 and poly IC, or PBS. Spleens were harvested and teased in the presence of collagenase, and splenocytes were enriched for CD11c+ cells through MACS+ selection, 
labeled for CD11c, B220, CD3, and DEC205, and sorted. CD11c+ B220− CD3− DEC+/DEC− subsets were collected and cultured with thy-1.1+ CFSE-labeled LACK TCR transgenic 
cells at a 1:5 ratio. αCD70 or nonreactive isotype mAb (3 μg/ml) was added to the cultures of DEC+ and DEC− DCs with LACK TCR transgenic cells at day 1 of co-culture. 
After 3.5 d, T cell priming was assessed by IL-4 and IFN-γ secretion. Representative of two individual experiments.1102  IL-12-INDEPENDENT, CD70-DEPENDENT IFN-γ SECRETION VIA DEC+ DCS | Soares et al.
indirect pathway where DEC+ DCs provide IL-12 used by 
DEC− DCs.
Effect of exogenous IL-12 on T cell responses to DC subsets
To determine whether IL-12 might supersede the CD70–
CD27 interaction for the induction of IFN-γ, we added 
1 ng/ml IL-12 p70 to cultures containing DC subsets that 
had been targeted with LACK in vivo. 1 ng/ml of exogenous 
IL-12 increased the production of IFN-γ by T cells stimulated 
with either DEC− or DEC+ DCs (Table II, bold data). How-
ever, the addition of IL-12 did not overcome the block to T 
cell proliferation and IFN-γ secretion that was imposed by 
αCD70 (Table II).
𝗂CD70 blocks the function of DEC+ DCs in vivo
To assess the need for CD70 by DEC+ DCs in vivo, we 
treated mice with αCD70 or isotype-matched control Ig 1 d 
before immunization with LACK. CD70 blockade did not 
alter the frequency of DEC+ or DEC− DCs (not depicted) 
but did completely abrogate priming via DEC-LACK but 
not 33D1-LACK (Fig. 6). As expected from its targeting to 
both DC subsets, LACK priming was only partially reduced 
by blocking CD70 in vivo. Therefore, CD70 interaction plays 
a major role in vivo during presentation of antigen to CD4+ 
T cells by DEC+ DCs.
DISCUSSION
Lymphocytes must diff  erentiate to produce eff  ector proteins 
like IFN-γ to bring about protective and pathologic forms of 
cell-mediated immunity. By selectively targeting antigen 
in the presence of αCD40 and poly IC to two major sub-
sets of DEC− and DEC+ DCs in situ, we fi  nd that there are 
two pathways to engage WT CD4+ T cells to make IFN-γ. 
DEC+ DCs are inherently disposed to induce IFN-γ in an 
IL-12–independent, CD70-dependent fashion. In contrast, 
DEC− DCs are disposed to induce IL-4 and IL-5, but will 
induce IFN-γ in a CD70-independent manner when exoge-
nous IL-12 is provided, e.g., from DEC+ DCs. These dis-
tinctions in DC subset function, which were documented 
both in vivo and in vitro, can be ascribed to the diff  erent DC 
subsets rather than the diff  erent DC receptors (DCIR2 and 
DEC) that we targeted because comparable functional dis-
tinctions were made with soluble antigen, which gained ac-
cess to both DC subsets and even isolated DCs presenting 
LACK peptide.
We considered the possibility that the observations were 
dependent on the type of maturation stimulus that was used. 
However, the distinct Th1- and Th2-polarizing functions of 
the two DC subsets were apparent when we obtained DCs 
from unstimulated mice, as documented previously by Pulen-
dran (8) and Moser (9). Likewise, maturation stimuli were not 
required for the DC subsets to exhibit diff  erent requirements 
for IL-12 and CD70 in culture. In vivo, DEC+ DCs have 
higher levels of TLR3 message. However, our data showed 
that DEC− DCs were responsive to poly IC, which served 
as a suitable stimulus for immune responses when the 33D1 
mAb targeted antigen to DEC− DCs (Fig. S3). Also, the dis-
tinct outcomes of antigen targeting to DC subsets in vivo 
were observed when LPS rather than poly IC was used. 
Therefore, the distinctions in the functions of DC subsets are 
intrinsic to these cells rather than the use of poly IC as a mat-
uration stimulus.
Our fi  nding that IL-12 is not mandatory for the Th1-
inducing function of DEC+ DCs would help to explain why 
IL-12 p40 KO mice are still able to induce IFN-γ (33–37). 
The ability of DEC+ DCs to induce IFN-γ in the absence of 
IL-12 also provides a potential mechanism for the ability of 
patients with genetic defi  ciencies in IL-12 or IL-12 receptor 
to produce IFN-γ and avoid infection with most intracellu-
lar pathogens (32).
The function of the DEC+ subset, although independent 
of IL-12 as a cytokine cofactor, was completely dependent 
on the membrane cofactor CD70. CD70 was up-regulated 
intracellularly by both DC subsets in mice given poly IC and 
anti-CD40 in the absence of LACK. However, CD70 was 
expressed selectively on the surface of DEC+ DCs when the 
DCs were presenting antigen to T cells. Although poly IC 
and anti-CD40 were required for optimal primary immune 
responses in vivo, these stimuli were not required for the DC 
subsets to exert their distinct functions in vitro, but again, 
Figure 6.  Contributions of CD70 to IFN-𝗄 secretion in response to 
DEC+ DCs in vivo. BALB/c mice were injected i.p. with 50 μg αCD70 
mAb 1 d before i.p. immunization with 10 μg DEC-LACK, 10 μg 33D1-
LACK, 50 μg LACK protein, and 10 μg Ig-LACK in the presence of αCD40 
and poly IC, or PBS. 3 wk later, the frequency of IFN-γ+ CD4+ CD3+ 
splenic T cells was determined by intracellular staining. One of two 
similar experiments.JEM VOL. 204, May 14, 2007  1103
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only the DEC+ DCs up-regulated CD70 expression when 
presenting antigen to T cells. This up-regulation was conse-
quential because anti-CD70 fully blocked IFN-γ production 
by DEC+ DCs in vitro and in vivo; in contrast, anti-CD70 
had no eff  ect on DEC− DCs. Further studies are needed to 
determine if the innate propensities of DC subsets to diff  er-
entially aff  ect the Th1/Th2 balance are independent of the 
maturation stimulus used. Our initial comparisons using poly 
IC and LPS as stimuli indicate that DC subset function is 
similar with these two TLR ligands.
Previous studies have emphasized a contribution of CD70 
to CD8+ T cell responses (50–58). In retrospect, the prior 
emphasis on CD8+ T cells might be attributed to the fact that 
the CD70-dependent DEC+ DC subset is the main DC that 
presents antigens on MHC class I products to CD8+ lympho-
cytes (21, 23, 26, 59). In contrast, although the DEC− subset 
more effi   ciently processes antigens onto MHC class II than 
the DEC+ subset (26), both DEC+ and DEC− DCs present 
antigen eff  ectively to CD4+ T cells. Previous studies have 
been unable to show (53, 60, 61) a CD70 requirement for 
IFN-γ production by CD4+ T cells. The contribution of 
CD70 to CD4+ T cell responses is probably more diffi   cult to 
discern when one gives a soluble antigen, which targets both 
CD70-dependent and -independent DCs. However, CD70 
emerges as an essential costimulator when DEC+ DCs are se-
lectively presenting antigen.
When we studied the points at which CD70 was used by 
DEC+ DCs to stimulate T cells, we found that blockade of 
this TNF family member did not aff  ect the initial DC–T cell 
interaction, as indicated by up-regulation of CD69 on T 
cells, an early activation marker. If anti-CD70 was added 
early to the culture, T cell proliferation was totally blocked, 
but if it was added 1 or 2 d later, IFN-γ was shut down but 
not T cell proliferation. Anti-CD70 blocked the function 
of DEC+ DCs with all forms of LACK antigen, i.e., DEC-
targeted LACK, nontargeted LACK, and even LACK peptide 
added in vitro. In contrast, anti-CD70 had no eff  ect on T 
cell stimulation by DEC− DCs that were presenting 33D1-
targeted LACK or nontargeted LACK protein or peptide. 
Importantly, CD70 was selectively expressed by DEC+ DCs. 
Additional research is required to identify a role for CD70 in 
response to infections and other challenges, but our data with 
antigen targeting indicate that a dominant role for CD70 in 
Th1 responses will only be observed when antigens are being 
presented predominantly by the DEC+ DC subset in lym-
phoid tissues. For example, a previous study has reported no 
role for CD70 during protection against infl  uenza (62), which 
is to be expected due to infl  uenza presentation by both CD8+ 
Table II.  IL-12 boosts IFN-γ production in DC–T cell cultures but does not overcome the block imposed by anti-CD70 on DEC+ 
DC function
Additions to cultures of WT15 LACK-specifi  c
CD4+ transgenic T cells
Form of LACK antigen to load DCs (IFN-𝗄 production at day 3.5 of DC–T cell co-culture; pg/ml)
𝗂DEC-LACK
10 𝗍g
33D1-LACK
10 𝗍g
Ig-LACK
10 𝗍g
LACK
30 𝗍g
None LACKpep
0.02 𝗍M
DEC+ DCs
no IL-12 IgG2b 1,022 −118 −174 478 −161 824
αCD70 −150 0 −33 5 −151 −4
+ IL-12 IgG2b 6,402 −54 0 1,115 23 3,333
αCD70 −53 0 3 10 15 27
DEC– DCs
no IL-12 IgG2b 0 −20 55 45 −14 0
0 −0.136 14 32 71 −121 61
+ IL-12
IgG2b 57 2,613 37 3,421 6 3,251
αCD70 49 3,324 −42 3,447 3 3,315
Additions to cultures of WT15 LACK-specifi  c
CD4+ TCR transgenic T cells
Form of LACK antigen to load DCs (IL-4 at day 3.5 in the medium of DC–T cell co-culture; pg/ml)
𝗂DEC-LACK
10 𝗍g
33D1-LACK
10 𝗍g
Ig-LACK
10 𝗍g
LACK
30 𝗍g
None LACKpep
0.02 𝗍M
DEC+ DCs
no IL-12 IgG2b 0 4 15 −74 −70 −27
αCD70 −36 2 2 11 −87 −30
+ IL-12 IgG2b −90 −95 −100 4 0 1
αCD70 −85 −72 −87 15 0 −13
DEC– DCs
no IL-12 IgG2b −60 334 −94 223 −98 422
αCD70 −36 284 −98 358 −70 451
+ IL-12 IgG2b −90 55 −85 70 −89 111
αCD70 −85 66 −99 64 −87.4 79
BALB/c mice (fi  ve mice per condition) were immunized for 10–12 h with αDEC-LACK, 33D1-LACK, Ig-LACK, and LACK protein in the presence of αCD40 and poly IC, or PBS. 
Spleens were harvested and teased in the presence of collagenase, and splenocytes were enriched for CD11c+ cells through MACS+ selection, labeled for CD11c, B220, CD3, 
and DEC205, and sorted. CD11c+ B220− CD3− DEC+/DEC− subsets were collected and cultured with thy-1.1+ CFSE-labeled LACK TCR transgenic cells at a 1:5 ratio. 1 ng/ml 
IL-12 and αCD70 or 3 μg/ml of nonreactive isotype mAb was added to the cultures of DEC+ and DEC− DCs with LACK TCR transgenic cells. After 3.5 d, T cell priming was 
assessed by IFN-γ secretion. Representative of three individual experiments.1104  IL-12-INDEPENDENT, CD70-DEPENDENT IFN-γ SECRETION VIA DEC+ DCS | Soares et al.
and CD8− DCs (63). We would like to suggest that CD70 is 
a “decision maker” for DEC+ DCs to induce Th1 T cell dif-
ferentiation by an IL-12–independent mechanism.
Even in the Th2-prone BALB/c mouse, our fi  ndings re-
veal that the mature DEC+ subset polarizes the T cell re-
sponse to the Th1 type (IFN-γ+ IL-4−). In contrast, the 
DEC− subset with the same DC maturation stimuli induces 
Th2 cytokines (IL-4 and IL-5) as well as IFN-γ. Although 
DEC+ DCs are a major source of IL-12 (for review see ref-
erences 2, 8, and 18), IL-12 ironically is not obligatory for 
the induction of IFN-γ by these DCs in vivo. In sections of 
human lymph nodes, CD11c+ DCs all express DEC, making 
this pathway a plausible one in humans (64). The targeting of 
vaccines to CD70-expressing DEC+ DCs should favor the 
development of Th1 immunity, a type of response consid-
ered to be valuable for protection against several global in-
fectious diseases.
MATERIALS AND METHODS
Mice. We used BALB/c mice from Taconic, IL-12 p40−/− from The Jackson 
Laboratory, WT15 BALB/c TCR transgenics specifi  c for the L. major pro-
tein LACK (39), and BALB/c thy-1.1 mice from M. and J. Lafaille (New 
York University, New York, NY). Mice were maintained under specifi  c 
pathogen-free conditions and used at 7–8 wk of age in accordance with In-
stitutional Animal Care and Use Committee guidelines.
Recombinant L. major LACK protein. The p24 fragment of LACK 
protein, whose sequence started at amino acid 136 of our construct, was 
produced by LACK-transformed Escherichia coli strain BL21CDE3 by iso-
propylthio-β-D-galactoside induction (Invitrogen). After LACK was puri-
fi   ed from lysates on NiATA-agarose columns (GE Healthcare), it was 
identifi  ed on SDS-PAGE and detoxifi  ed on LPS columns (Detoxigel Endo-
tosing Removing Gel [Pierce Chemical Co.]; Limulus Amebocyte Lysate 
assay, QCL-1000 [Bio Whittaker]).
Fusion mAbs containing L. major LACK protein. DNA from L. major 
LACK protein (39) was cloned in frame into the C terminus of αDEC-205, 
33D1, and control mAb heavy chains (10, 26). The fusion mAbs were ex-
pressed by transient transfection (calcium phosphate) in 293 cells in serum-
free DMEM supplemented with Nutridoma SP (Roche), purifi  ed on protein 
G columns (GE Healthcare), and characterized by SDS-PAGE and Western 
blotting (horseradish peroxidase sheep anti–mouse Ig; GE Healthcare). The 
unmodifi  ed heavy and light chains of the α-DEC205 mAb were likewise 
expressed and purifi  ed. All mAbs were endotoxin free.
Antigen targeting and maturation of DCs in vivo. BALB/c mice were 
injected i.p. or s.c. (footpads) with LACK fusion mAbs or protein ± stimuli 
for DC maturation, which were 50 μg poly IC (InVivoGen) and 25 μg 
1C10 agonistic αCD40 (65). Alternatively, a combination of αCD40 and 
50 μg LPS or 20 μg TLR7/8 agonist was used in some experiments. These 
stimuli all led to the up-regulation of several costimulatory molecules on 
splenic DCs in vivo, such as CD40 and CD86.
LACK peptide libraries. Overlapping (staggered by 4 amino acids) 15-mer 
peptides spanning the entire LACKp24 sequence were synthesized by the 
Proteomics Resource Center (The Rockefeller University). The 51-member 
L. major LACK library was divided into 5 pools of 10 peptides each, except 
the last pool contained 11 peptides.
Assays for LACK-specifi  c CD4+ T cells. Spleen cells were restimulated 
with pools of peptides (2 μg/ml) or medium alone, along with 2 μg/ml of 
costimulatory αCD28 (clone 37.51) for 6 h. 10 μg/ml brefeldin A (Sigma-
Aldrich) was added for the last 4 h. Cells were washed, incubated for 15 min 
at 4°C with 2.4G2 mAb to block FcγR, and stained with FITC αCD3 (145-
2C11) and PE- or PerCP-conjugated αCD4 (RM4-5) for 20 min at 4°C. 
The cells were permeabilized (Cytofi  x/Cytoperm Plus; BD Biosciences) and 
stained with APC-αIFNγ (XMG 1.2) at room temperature (BD Bio-
sciences). We used a FACSCalibur with data analysis in FlowJo (Tree Star). 
In some experiments, BALB/c mice were injected i.p. with 50 μg anti-
CD70 mAb (FR70) or isotype control 1 d before immunization with the 
various forms of LACK antigen. All plots were gated on CD3+ T cells. For 
ELISPOT assays, we restimulated positively selected CD4+ T cells with 
CD11c+ spleen DCs and LACK peptide pools, LACK-immunodominant 
peptide, or medium alone for 36 h. DCs were enriched from spleens dissoci-
ated with collagenase (collagenase D; Roche) using αCD11c-coated mag-
netic beads (Miltenyi Biotec).
IgG isotype ELISA. High-binding ELISA plates (Costar) were coated 
overnight with 5 μg/ml LACK protein in PBS. Plates were washed three 
times with PBS-Tween 20 0.02% and blocked with PBS-BSA 1% for 1 h at 
room temperature. Serial dilutions of the sera in PBS-BSA 0.25% were in-
cubated for 2 h at room temperature and visualized with goat anti–mouse 
subclass-specifi  c antibodies conjugated to horseradish peroxidase (1:500; 
SouthernBiotech), followed by colorimetric assay using 1-Step ABTS. OD405 
was measured using an OPSYS Mr microplate reader (ThermoLab Systems). 
Titers represent highest dilution of serum showing an OD405 of >0.1 and are 
presented as the log10 antibody titer of each mouse.
Presentation to LACK-specifi   c TCR transgenic CD4+ T cells. 
CD11c+ cells from draining lymph nodes and spleens from mice that had 
been injected 12–16 h previously with diff  erent forms of LACK antigen or 
106 L. major metacyclic promastigotes were positively selected (Miltenyi 
Biotec) using αCD11c-coated magnetic beads. Graded doses of CD11c+ DCs 
or their subsets (see below) were added to 105 WT15 TCR transgenic T cells 
(negatively selected with anti–MHC class II and anti-CD8) labeled with 
CFSE (107 cells/ml, 1 μM for 10 min at 37°C; Invitrogen) in round-bottom 
96-well plates. For in vivo studies, the T cells were labeled with 5 μM CFSE, 
and 3 × 106 thy-1.1+ marked cells were i.v. injected into BALB/c thy-1.2+ 
recipient mice. 24 h later, diff  erent forms of LACK or 106 L. major meta-
cyclic promastigotes were injected i.p. or s.c. into the hind footpads. Spleno-
cytes were analyzed for proliferation and cytokine production 6 d later.
In vitro diff  erentiation of LACK-specifi  c, TCR-transgenic CD4+ 
T cells. 12–16 h after injection of diff  erent forms of LACK, CD11c+ cells were 
selected (Miltenyi Biotec) as described above and sorted on a FACSVantage 
(BD Biosciences) into B220− CD3− CD11chigh DEC205high and B220− 
CD3− CD11chigh DEC205low fractions (>99% pure). 6 × 104 DCs were cul-
tured for 3.5 d with 3 × 105 CFSE-labeled WT 15 TCR transgenic cells in 
round-bottom 96-well plates. Cytokines were detected by APC–anti–IFN-γ 
(XMG 1.2) intracellular cytokine staining or by ELISAs with mAbs specifi  c 
for IL-4, IFN-γ, IL-5, and IL-2 (BD OpTEIA; BD Biosciences). 5 ng/ml of 
mouse rIL-12 (R&D Systems) was added in some experiments.
Fusion mAbs containing Plasmodium yoelli circumsporozoite protein. 
These were cloned as described previously (44) and expressed by transient 
transfection (calcium phosphate) according to the same protocol for fusion 
mAbs containing LACK protein.
Online supplemental material. Fig. S1 shows mAb characterization. Fig. S2 
shows αDEC-LACK presentation by CD11c+, but not by CD11c−, cells 
from draining lymph nodes. Fig. S3 shows that a combination of αCD40 and 
TLR3 agonist, poly IC, confers optimal IFN-γ production by LACK antigen–
primed CD4+ T cells. Fig. S4 shows DC targeting as a strategy to effi   ciently 
prime CD4+ T cells. Fig. S5 shows LACK protein–unique immunodominant 
CD4+ epitope. Fig. S6 shows that αCD70 blocks T cell proliferation and 
IFN-γ secretion by DEC+ DCs, but not DEC– DCs, from IL-12 p40 KO 
mice in vivo. Fig. S7 shows CD70 expression on DEC+ and DEC− DCs. Fig. S8 JEM VOL. 204, May 14, 2007  1105
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shows CD70 expression on LACK transgenic cells. Figs. S1–S8 are available 
at http://www.jem.org/cgi/content/full/jem.20070176/DC1.
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